# An Observational Study Called FIRST-2.0 China to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions in a Chinese Population.

> **NCT07124039** · — · COMPLETED · sponsor: **Bayer** · enrollment: 6537 (actual)

## Conditions studied

- Chronic Kidney Disease
- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Finerenone (Kerendia, BAY948862)

## Key facts

- **NCT ID:** NCT07124039
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-07-16
- **Primary completion:** 2026-02-28
- **Final completion:** 2026-02-28
- **Target enrollment:** 6537 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07124039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07124039, "An Observational Study Called FIRST-2.0 China to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions in a Chinese Population.". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT07124039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*